Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fulcrum Therapeutics Inc FULC

Healthcare Biotechnology
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX... see more

Recent & Breaking News (NDAQ:FULC)

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

ACCESS Newswire June 9, 2023

FULC SHAREHOLDER ALERT: Jakubowitz Law Reminds Fulcrum Shareholders of a Lead Plaintiff Deadline of June 27, 2023

PR Newswire June 9, 2023

Lawsuits Filed Against FULC, Stem and FNKO - Jakubowitz Law Pursues Shareholders Claims

ACCESS Newswire June 8, 2023

ROSEN, Leading Investor Counsel, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FULC

Newsfile June 8, 2023

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile June 8, 2023

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

ACCESS Newswire June 8, 2023

FULC LAWSUIT ALERT: Levi & Korsinsky Notifies Fulcrum Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

PR Newswire June 8, 2023

INVESTOR REMINDER: Berger Montague Advises Fulcrum Therapeutics, Inc. (FULC) Investors to Inquire About a Securities Fraud Class Action Lawsuit by June 27, 2023

Newsfile June 7, 2023

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - FULC

Newsfile June 7, 2023

SHAREHOLDER ALERT: FULC CGC CUTR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

ACCESS Newswire June 7, 2023

INVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile June 7, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

ACCESS Newswire June 7, 2023

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Fulcrum Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 27, 2023 - (NASDAQ: FULC)

PR Newswire June 7, 2023

FULCRUM THERAPEUTICS, INC. (FULC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fulcrum Therapeutics, Inc.

Newsfile June 7, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile June 6, 2023

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses to Contact the Firm

ACCESS Newswire June 6, 2023

FULC ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 27, 2023 in the Class Action Filed on Behalf of Fulcrum Therapeutics, Inc. Shareholders

PR Newswire June 6, 2023

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Fulcrum Investors of a Lead Plaintiff Deadline of June 27, 2023

PR Newswire June 5, 2023

LAWSUITS FILED AGAINST HBNC, LPSN and FULC - Jakubowitz Law Pursues Shareholders Claims

ACCESS Newswire June 5, 2023

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Fulcrum Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile June 5, 2023